查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球新生儿筛检市场
市场调查报告书
商品编码
1380456

2023-2030 年全球新生儿筛检市场

Global Newborn Screening Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 175 Pages | 商品交期: 2-3个工作天内

价格

全球新生儿筛检市场预计在预测期内（2023-2030年）CAGR为7.8%。市场的成长归功于早期介入。在医疗保健领域，早期介入对于改善患者的治疗效果变得越来越重要。现代科技有助于实现新生儿筛检的基本目标。因此，市场参与者正在推出新产品来满足对新筛检设备的需求。例如，2023 年 9 月，MyLab 推出了一款革命性的护理点新生儿筛检设备，名为 My NeoShield，用于新生儿筛检。该技术预计将改变新生儿保健的方法，促进更快、更容易、更经济的筛检，最终可以挽救生命并防止疾病发展为终身疾病。该设备支援全球新生儿筛检所使用的所有七项测试。

细分市场前景

全球新生儿筛检市场按技术、测试类型和最终用户进行细分。根据技术，市场细分为串联质谱、LC-MS/MS、脉搏血氧测定、DNA 微阵列和 NGS、酵素检测等。根据测试类型，市场细分为血斑筛检（干血斑测试）、听力筛检（耳声发射和听性脑干反应）、脉搏血氧饱和度筛检、CCHD 等。此外，根据最终用户，市场被细分为医院和分娩中心、NIUC、诊断中心、研究人员和科学家等。医院和分娩中心子类别预计将占据最终用户领域的很大一部分市场份额。可支配收入的增加、患者住院需求的增加、新生儿疾病盛行率的增加、高科技医院和医疗基础设施的发展是推动市场成长的其他因素。

听力筛检细分市场预计将在全球新生儿筛检市场中占据相当大的份额

在测试类型中，听力筛检细分市场预计将在全球新生儿筛检市场中占据相当大的份额。节段性增长归因于新生儿听力损失的普遍存在。上述比率强调了新生儿听力筛检计划的重要性。根据美国国立卫生研究院(NIH.gov) 的数据，2022 年10 月，每1000 名活产婴儿中，有1 至1.5 次发生新生儿患有严重或深度PBHL（损失>60 dB [dB]）的情况。每 1000 名婴儿中，有 1 至 2 名婴儿出现双侧轻度至中度听力损失或任何严重程度的单侧听力损失。严重和深度 PBHL 都会严重阻碍语言和识字能力的发展、成人功能和生活品质.

区域展望

全球新生儿筛检市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本） 、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于存在强大的市场竞争对手、有利的报销政策以及新生儿筛检计划的可用性，预计北美将在全球市场中占据显着份额。

欧洲地区全球新生儿筛检市场预计将以显着的复合CAGR成长

在所有地区中，欧洲地区预计在预测期内将以相当大的CAGR成长。区域成长归因于该地区诊断效率的不断提高。新生儿全基因组定序是一种有效的诊断工具，可以发现多种遗传异常，甚至罕见疾病。透过早期检测和干预，这种程度的诊断准确性可以大大提高新生儿筛检的效率。政府和该地区的市场参与者越来越多地引入此类新的诊断工具和倡议，以提供更好的新生儿医疗保健服务。例如，2022 年 12 月，英国政府启动了新生儿基因组计划，这是一项新研究，旨在检验全基因组定序在识别新生儿罕见疾病方面的效率。除了血斑检测之外，新生儿的全基因组定序还发现了数千种罕见疾病，并显着改善了患有上述疾病的儿童的生活品质。欧洲市场参与者和政府正在透过部署不同的行销策略为新生儿筛检市场的快速发展创造有利条件。

此外，2021年9月，英国公共卫生部（PHE）、英国国家筛检委员会（UK NSC）、英国国民医疗服务体系（NHS England）和国民保健服务改善局（NHSEI）在英国启动了针对新生儿严重联合免疫缺陷（SCID）血斑筛检的评估。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • At Demant A/S,
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Bio-Rad Laboratories, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • GE HealthCare Technologies Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按技术分類的全球新生儿筛检市场
    • 串联质谱法
    • 液相层析质谱联用 (LC-MS/MS)
    • 脉搏血氧仪
    • DNA 微阵列和次世代定序 (NGS)
    • 基于酵素的测定
    • 其他（高效液相层析法 (HPLC)、免疫比浊法和免疫化学）
  • 按测试类型分類的全球新生儿筛检市场
    • 血斑筛检（干血斑测试）
    • 听力筛检（耳声发射和听觉脑干反应）
    • 脉搏血氧仪筛检
    • 严重先天性心臟缺陷 (CCHD)
    • 其他（甲状腺功能测试、汗液氯化物测试和凝血研究（PT/INR 和 APTT）
  • 按最终用户分類的全球新生儿筛检市场
    • 医院和分娩中心
    • 新生儿加护病房 (NICU)
    • 诊断中心
    • 研究人员和科学家
    • 其他（医疗保健管理员、医生和儿科医生以及实验室）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Hill-Rom Holdings, Inc.,
  • India Medtronic Pvt. Ltd.
  • Integrated DNA Technologies
  • LifeCell International Pvt. Ltd.
  • Masimo Corp.
  • PerkinElmer AES
  • SCIEX
  • Thermo Fisher Scientific Inc.,
  • Trivitron Healthcare
  • WATERS CORP.
  • ZenTech SA
Product Code: OMR2027763

Title: Global Newborn Screening Market Size, Share & Trends Analysis Report by Technology (Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry (LC-MS/MS), Pulse Oximetry, DNA Microarrays and Next-Generation Sequencing (NGS), Enzyme Based Assays, and Others), by Test Type (Blood Spot Screening, Hearing Screening, Pulse Oximetry Screening, Critical Congenital Heart Defect (CCHD), and Others), and by End-User (Hospitals and Birthing Centers, Neonatal Intensive Care Units (NICUs), Diagnostic Centers, Researchers and Scientists, and Others)Forecast Period (2023-2030).

The global newborn screening market is anticipated to grow at a CAGR of 7.8% during the Forecast Period (2023-2030). The market's growth is attributed to early intervention. Early intervention has become more and more essential in healthcare to enhance patient outcomes. Modern technologies help to achieve the essential goal of newborn screening. Accordingly, market players are coming up with new products to cater to the demand for new screening devices. For instance, in September 2023, MyLab introduced a revolutionary point-of-care newborn screening device named My NeoShield for newborn screening. The technology is expected to change the methods by that neonatal healthcare is provided by facilitating quicker, easier, and more economical screening, that can ultimately save lives and prevent diseases from developing into lifelong conditions. All seven tests used for newborn screening across the globe are supported by the device.

Segmental Outlook

The global newborn screening market is segmented on the technology, test type, and end-user. Based on the technology, the market is sub-segmented into tandem mass spectrometry, LC-MS/MS, pulse oximetry, DNA microarrays and NGS, enzyme based assays, and others. Based on the test type, the market is sub-segmented into blood spot screening (dried blood spot test), hearing screening (otoacoustic emissions and auditory brainstem response), pulse oximetry screening, CCHD, and others. Furthermore, based on the end-user, the market is sub-segmented into hospitals and birthing centers, NIUCs, diagnostic centers, researchers and scientists, and others. The hospitals and birthing centers subcategory is expected to capture a significant portion of the market share within the end-user segment. Rising disposable income along with a rise in patient hospitalization needs, increased prevalence of newborn diseases high-tech hospitals and healthcare infrastructure developments are additional factors propelling the market's growth.

The Hearing Screening Sub-Segment is Anticipated to Hold a Considerable Share of the Global Newborn Screening Market

Among the test types, the hearing screening sub-segment is expected to hold a considerable share of the global newborn screening market. The segmental growth is attributed to the prevalence of newborn hearing loss. The significance of newborn hearing screening programs is emphasized by the aforementioned rate. According to the National Institute of Health (NIH.gov), in October 2022, it occurs 1 to 1.5 times per 1000 live births when a neonate has severe or profound PBHL (loss of >60 dB [dB]). Bilateral mild to moderate hearing loss or unilateral hearing loss of any severity affects 1 to 2 more infants every 1000. The development of language and literacy, adult functioning, and quality of life are all significantly hindered by both severe and profound PBHL.

Regional Outlook

The global newborn screening market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of strong market competitors, advantageous reimbursement policies, and the availability of newborn screening programs.

The European Region is Expected to Grow at a Significant CAGR in the Global Newborn Screening Market

Among all regions, the European region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising improvement in diagnostic efficiency across the region. Newborns' whole genome sequencing is an effective diagnostic tool that can spot a variety of genetic abnormalities, even rare diseases. By enabling early detection and intervention, this degree of diagnostic accuracy can considerably improve the efficiency of newborn screening. The government along with the market players operating in the region are increasingly introducing such new diagnostic tools and initiatives to provide improved newborn healthcare services. For instance, in December 2022, the UK Government launched the Newborn Genomes Programme, a new study that examines the efficiency of whole genome sequencing in identifying uncommon disorders in newborn babies. In addition to the blood spot test, whole genome sequencing of newborns identified thousands of uncommon diseases and significantly improved the quality of life for children born with the aforementioned conditions. European market players and governments are creating favorable conditions for the rapid development of the newborn screening market by deploying different marketing strategies.

Furthermore, in September 2021, Public Health England (PHE), the UK National Screening Committee (UK NSC), NHS England, and NHS Improvement (NHSEI) launched an evaluation of newborn blood spot screening for severe combined immunodeficiency (SCID) in England.

Market Players Outlook

The major companies serving the newborn screening market include: Hill-Rom Holdings, Inc., India Medtronic Pvt. Ltd., Integrated DNA Technologies, LifeCell International Pvt. Ltd., Masimo Corp. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2023, Eight taluk hospitals announced to launch a newborn screening. For which, the Mysuru-based All India Institute of Speech and Hearing (AIISH) collaborated with the Department of Health and Family Welfare for briefing the medical teams working under Rashtriya Bal Swasthya Karyakram (RBSK) and District Early Intervention Centre (DEIC) on screening communication disorders in children. The initiative is introduced post recognizing the need for expanding the Newborn Screening Programme (NBS).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global newborn screening market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. At Demant A/S,
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Bio-Rad Laboratories, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. GE HealthCare Technologies Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Newborn Screening Market by Technology
    • 4.1.1. Tandem Mass Spectrometry
    • 4.1.2. Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
    • 4.1.3. Pulse Oximetry
    • 4.1.4. DNA Microarrays and Next-Generation Sequencing (NGS)
    • 4.1.5. Enzyme Based Assays
    • 4.1.6. Others (High-Performance Liquid Chromatography (HPLC), and Immunoturbidimetry and Immunochemistry)
  • 4.2. Global Newborn Screening Market by Test Type
    • 4.2.1. Blood Spot Screening (Dried Blood Spot Test)
    • 4.2.2. Hearing Screening (Otoacoustic Emissions and Auditory Brainstem Response)
    • 4.2.3. Pulse Oximetry Screening
    • 4.2.4. Critical Congenital Heart Defect (CCHD)
    • 4.2.5. Others (Thyroid Function Testing, Sweat Chloride Test, and Coagulation Studies (PT/INR and APTT)
  • 4.3. Global Newborn Screening Market by End-User
    • 4.3.1. Hospitals and Birthing Centers
    • 4.3.2. Neonatal Intensive Care Units (NICUs)
    • 4.3.3. Diagnostic Centers
    • 4.3.4. Researchers and Scientists
    • 4.3.5. Others (Healthcare Administrators, Physicians and Pediatricians, and Laboratories)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Hill-Rom Holdings, Inc.,
  • 6.2. India Medtronic Pvt. Ltd.
  • 6.3. Integrated DNA Technologies
  • 6.4. LifeCell International Pvt. Ltd.
  • 6.5. Masimo Corp.
  • 6.6. PerkinElmer AES
  • 6.7. SCIEX
  • 6.8. Thermo Fisher Scientific Inc.,
  • 6.9. Trivitron Healthcare
  • 6.10. WATERS CORP.
  • 6.11. ZenTech SA

LIST OF TABLES

  • 1. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 2. GLOBAL TANDEM MASS SPECTROMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PULSE OXIMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL DNA MICROARRAYS AND NEXT-GENERATION SEQUENCING NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL ENZYME BASED ASSAYS NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL OTHERS NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 9. GLOBAL NEWBORN BLOOD SPOT SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL NEWBORN HEARING SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL NEWBORN CRITICAL CONGENITAL HEART DEFECT SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL NEWBORN OTHERS SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 14. GLOBAL NEWBORN SCREENING FOR HOSPITALS AND BIRTHING CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL NEWBORN SCREENING FOR NEONATAL INTENSIVE CARE UNITS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL NEWBORN SCREENING FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL NEWBORN SCREENING FOR RESEARCHERS AND SCIENTISTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL NEWBORN SCREENING FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 24. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL NEWBORN SCREENING MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 2. GLOBAL TANDEM MASS SPECTROMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PULSE OXIMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL DNA MICROARRAYS AND NEXT-GENERATION SEQUENCING NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL ENZYME BASED ASSAYS NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL OTHERS NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL NEWBORN SCREENING MARKET SHARE BY TEST TYPE, 2022 VS 2030 (%)
  • 9. GLOBAL NEWBORN BLOOD SPOT SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL NEWBORN HEARING SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL NEWBORN CRITICAL CONGENITAL HEART DEFECT SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL NEWBORN OTHERS SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL NEWBORN SCREENING MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 14. GLOBAL NEWBORN SCREENING FOR HOSPITALS AND BIRTHING CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL NEWBORN SCREENING FOR NEONATAL INTENSIVE CARE UNITS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL NEWBORN SCREENING FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL NEWBORN SCREENING FOR RESEARCHERS AND SCIENTISTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL NEWBORN SCREENING OTHERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 20. US NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)